Sugi Predict

Sugi Predict / Compounds / SCHEMBL3171

SCHEMBL3171

SCHEMBL3171

COC(=O)C1CCCCC1=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.54
▸ MCL1 Q07820 1/20 0.49
▸ KDM4E B2RXH2 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA4 P22748 1/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ HTT P42858 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP1A2 P05177 2/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ RECQL P46063 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HIF1A Q16665 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20303983 1.00 MAPK1 (0.54) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL7305358 1.00 MAPK1 (0.54) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL1615850 0.98 MAPK1 (0.53) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL3767660 0.98 MAPK1 (0.53) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL6248372 0.98 MAPK1 (0.53) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL7199566 0.98 MAPK1 (0.53) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL27922653 0.98 MAPK1 (0.53) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL374935 0.94 MAPK1 (0.47) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL31276435 0.94 MAPK1 (0.47) MAPK1MCL1KDM4EHSD17B10CA1
SCHEMBL25061 0.94 MAPK1 (0.47) MAPK1MCL1KDM4EHSD17B10CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285528-B Synthesis method of 1, 2-cyclopentanediimide 济南大学 2025-05-09 — — CN claimed
CN-119285528-A Synthesis method of 1, 2-cyclopentanediimide 济南大学 2025-01-10 — — CN claimed
US-20240400792-A1 CURABLE (METH)ACRYLATE COMPOSITIONS HENKEL AG & CO KGAA (DE) 2024-12-05 — — US claimed
CN-118355086-A Curable (meth) acrylate composition 汉高股份有限及两合公司 2024-07-16 — — CN claimed
WO-2023104819-A1 CURABLE (METH) ACRYLATE COMPOSITIONS Henkel IP & Holding GmbH (DE) 2023-06-15 — — WO claimed
CN-107849219-B Blocked polyisocyanate composition based on 1, 5-pentamethylene diisocyanate 科思创德国股份有限公司 2021-11-19 — — CN claimed
CN-102603727-B A kind of synthetic method of benzothiazole derivant CHENGDU MEDICAL COLLEGE (CN) 2016-05-04 — — CN claimed
US-6166173-A Biodegradable polymers chain-extended by phosphates, compositions, articles and methods for making and using the same GUILFORD PHARMACEUTICALS INC. (US) 2000-12-26 — — US claimed
US-20260014146-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CEDILLA THERAPEUTICS INC (US) 2026-01-15 — — US disclosed
US-20250326731-A1 CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS SCRIPPS RESEARCH INST (US) 2025-10-23 — — US disclosed
US-20250289837-A1 MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS UNIV LJUBLJANI (SI) 2025-09-18 — — US disclosed
CN-120114443-A Caspase-2 small molecule agonist and application thereof 北京生命科学研究所 2025-06-10 — — CN disclosed
EP-4562014-A2 CDK2 INHIBITORS AND METHODS OF USING THE SAME Cedilla Therapeutics, Inc. (US) 2025-06-04 — — EP disclosed
US-20250163030-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES GILEAD SCIENCES, INC. 2025-05-22 — — US disclosed
US-4785132-A CATALYTIC HYDROGENATION OF HYDROXYBENZOIC ACIDS MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1988-11-15 — — US disclosed
EP-0257727-A1 Process for preparing cyclohexanonecarboxylic acid compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1988-03-02 — — EP disclosed
US-4352800-A ANTIBIOTICS, BLOOD KYOTO YAKUHIN KYOGO KABUSHIKI KAISHA (JP) 1982-10-05 — — US disclosed
US-4277465-A ENAMINE DERIVATIVE KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1981-07-07 — — US disclosed
EP-0009609-A2 Adjuvant for promoting absorption of therapeutically active substances through the digestive tract, pharmaceutical composition comprising said adjuvant and process for preparing said pharmaceutical composition; enamine derivatives KYOTO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1980-04-16 — — EP disclosed
US-4124373-A Tetrahydroindazole herbicides E. I. DU PONT DE NEMOURS AND COMPANY (US) 1978-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326731-A1 CATALYST-CONTROLLED SITE-SELECTIVE METHYLENE C-H LACTONIZATION OF DICARBOXYLIC ACIDS DNPH1, NISCH, PTMA MAPK1 2929/4885MCL1 454/4885KDM4E 1635/4885
US-20250289837-A1 MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS KCNJ2, KCNN3, KCNA3 MAPK1 1215/4885MCL1 59/4885KDM4E 1417/4885
US-20250163030-A1 PYRIDIZIN-3(2H)-ONE DERIVATIVES PIR, CYP3A43, CYP1A2 MAPK1 1428/4885MCL1 936/4885KDM4E 3408/4885
US-20260014146-A1 CDK2 INHIBITORS AND METHODS OF USING THE SAME CDK2, CDK20, CDK1 MAPK1 306/4885MCL1 491/4885KDM4E 3468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.